# Zenhale Inhaled Corticosteroid Therapy: Useful Second Line Therapy for Asthma in Children but be Wary of Adrenal Suppression

Rebecca Perry<sup>1,3</sup>, Wendy Schwarz<sup>1</sup>, Karen Stosky<sup>2</sup>, Jonathan Dawrant<sup>1</sup> Daniele Pacaud<sup>1,3</sup>, Mary Noseworthy<sup>2,3</sup> & Mark Anselmo<sup>2,3</sup>

1. Division of Endocrinology 2. Division of Respiratory Medicine, Department of Pediatrics, University of Calgary 3. Alberta Children's Hospital Research Institute for Child and Maternal Health; Calgary, AB, Canada



The authors have **no** financial disclosures that would be a potential conflict of interest with this presentation.

#### INTRODUCTION

- Inhaled corticosteroids (ICS) are the most effective treatment of chronic persistent asthma in adults and children.<sup>1</sup>
- Children with Asthma who do not respond to first-line therapy may need ICS-Long-Acting Beta Agonist (ICS-LABA) combination therapy.
- Adrenal insufficiency (AI) due to adrenal suppression is a recognized side effect of ICS therapy<sup>2-5</sup> but clinically significant suppression is rare.<sup>6</sup>
- An increase in suspected cases of AI associated with one particular ICS-LABA, mometasone-formoterol (Zenhale) was observed at a tertiary care Asthma clinic over a 6-month period.

## **OBJECTIVE**

To identify the prevalence of adrenal insufficiency in children treated with Zenhale.

#### **METHODS**

#### Patients

- After confirmation of AI in the index patients by low-dose synthetic ACTH stimulation testing (LDST) all remaining children attending the Asthma Clinic at Alberta Children's Hospital (ACH) treated with Zenhale were identified using the respiratory database.
- Subjects were then contacted by Respiratory clinic staff and screened for possible symptoms of AI and requested to perform an 8 am plasma cortisol.
- Children with symptoms suggestive of adrenal insufficiency and/or low 8 am plasma cortisol levels (<200 nmol/L) were reviewed by Endocrinology and underwent a LDST Biochemistry

#### Plasma Cortisol

 Measured using Roche Modular Analytics E170 platform (Roche Diagnostics) with chemiluminescent competitive assay: functional sensitivity 0.5 nmol/L and coefficient of variation (CV): mean of 110 nmol/L CV, 6.4%; mean of 595 nmol/L CV, 3.3% and for mean of 900 nmol/L CV, 3%. Reference range: 200-690 nmol/L.

## LDST

- 1 microgram of Cosyntropin was administered, after serial dilution, by IV injection and plasma cortisol samples obtained at baseline, 30 and 60 minutes post-injection.
- Peak cortisol level of <500 nmol/L was considered an impaired response.</li>

## Statistics

SPSS Version 19

- Groups were compared using independent t-tests.
- Receiver operating characteristic (ROC) curve
- Generated to assess 8 am plasma cortisol as a diagnostic screening test.

#### RESULTS

- 170 children in the Asthma clinic were prescribed Zenhale.
- 12 children prescribed Zenhale are not included: as they never started or had previously discontinued the medication.
- Screening has been completed in 111 children; 39 had LDST of which 16 (14.4 %) had adrenal insufficiency (see Table).
- In the <6 years sub-group, 9 of 21 children screened (42.9%) had adrenal insufficiency; and 9 of 10 children (90%) screened on high dose Zenhale (800 mcg/day) had Al.

		N	8am Plasma Cortisol (nmol/L)	Peak Cortisol on LDST (nmol/L)	Age (y)	Zenhale	
						Dose (mcg/day)	Duration (y)
Low 8am Cortisol &/or Al symptoms	Adrenal suppression	16	12 (2-255)	216 (11-398)	5.7 (3.3-12.6)*	800 (400-800)*	0.7 (0.3-2)
	No adrenal suppression	24	147 (3-321)	654 (503-890)	9.4 (3.9-14.0)	400 (200-800)	0.8 (0.3-2)
Normal 8am Cortisol & no Al symptoms		72	372 (203-747)	N/A	10.9 (2.5-17.5)	400 (200-800)	1.1 (0.02-2.6)
No screening performed		46	N/A	N/A	11.1 (2.4-17.3)	400 (200-800)	1.2 (0.2-3.3)

**Table:** Characteristics of all subjects described as median (range)

\*denotes *P*<0.01 *vs.* no suppression (N=96)

#### RESULTS cont.

- Relative Risk of adrenal insufficiency with Dose ≥ 600 mcg/d was 11.3 (95% CI: 2.7-47.4)
- Relative Risk of adrenal insufficiency in Age <6yr was 6.5 (95 % CI: 2.6-16.3)</li>

## 8 am Plasma Cortisol as a diagnostic screening test?

- ROC curve was generated using various cut-offs of plasma cortisol to assess its use as a diagnostic screening test (see Figure)
- According to ROC curve best cut-off was 50 nmol/L with the following characteristics:

Sensitivity 0.86 (95% CI: 0.79-0.92) Specificity 0.95 (95% CI: 0.90-0.99)

Positive predictive value 0.71 Negative predictive value 0.98

Likelihood ratio 16.1 (95% CI: 6.69-38.82)




Figure: ROC curve for 8am Plasma Cortisol

#### CONCLUSIONS

- Zenhale is an effective second-line Asthma medication but its use in children has been complicated by adrenal suppression in 14% of a pediatric population.
- The relative risk is unacceptably high with a dose ≥ 600 mcg/day and children <6 years
- We recommend a maximum daily dose of 400 mcg in children <12 years and caution in those <6 years based on these data.
- Children/adolescents using Zenhale <12 years or on high daily doses (>400 mcg) should be advised about: signs and symptoms of AI and to avoid abruptly stopping Zenhale therapy and to discuss any dose changes with their Asthma team.
- 8 am plasma cortisol is an acceptable screening test for adrenal insufficiency in this scenario if the 50 nmol/L cut-off is employed vs. lower limit of normal range but cannot exclude adrenal insufficiency and patients with suggestive symptoms should still be referred to Endocrinology.

## REFERENCES

- 1. Calpin C, Macarthur C, Stephens D, Feldman W, Parkin PC. Effectiveness of prophylactic inhaled steroids in childhood asthma: a systemic review of the literature. J Allergy Clin Immunol 1997;100:452-7.
- 2. Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002;87:457-61.
- 3. Donaldson MD, Morrison C, Lees C, McNeill E, Howatson AG, Paton JY, McWilliam R. Fatal and near-fatal encephalopathy with hyponatraemia in two siblings with fluticasone-induced adrenal suppression. Acta Paediatr 2007;96:769-72.
- Paton J, Jardine E, McNeill E, Beaton S, Galloway P, Young D, Donaldson M. Adrenal responses to low dose synthetic ACTH (Synacthen) in children receiving high dose inhaled fluticasone. Arch Dis Child 2006;91:808-13.
- 5. Mahachoklertwattana P, Sudkronrayudh K, Direkwattanachai C, Choubtum L, Okascharoen C. Decreased cortisol response to insulin induced hypoglycaemia in asthmatics treated with inhaled fluticasone propionate. Arch Dis Child 2004;89:1055-8.
- 6. Allen DB. Effects of inhaled steroids on growth, bone metabolism and adrenal function. Adv Pediatr. 2006;53:101-10.

## CONTACT

Rebecca Perry, MB ChB rebecca.perry@albertahealthservices.ca

Mark Anselmo, MD mark.anselmo@albertahealthservices.ca

